NuCana plc has published its Annual Report for the year ended 31 December 2024. The report outlines the company's ongoing commitment to improving cancer treatment outcomes using its ProTide™ technology, which aims to enhance the efficacy and safety of widely used chemotherapy agents. The report also notes a recent change in the company's listing, with its American Depositary Shares now traded on The Nasdaq Capital Market under the symbol "NCNA". The full report can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.